Biosergen

Biosergen Net Margin

The Net Profit Margin of Biosergen (BIOSGN.ST) as of Oct 18, 2026 is -403.10 %. In the previous year, Net Profit Margin was -162.95 % — a change of 147.38% (lower).

Net Margin

-403.10 %

YoY

147.38%

Last updated:

Net Profit Margin of Biosergen is 2021 -403.10 % . Net Profit Margin of Biosergen was 2020 -162.95 % . It decreases by 147.38% lower compared to the previous year.

Biosergen's net margin stands at -403.1%, up from -412.5% several years earlier.

The Biosergen Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2019
-412.48 SEK
Jan 1, 2020
-162.95 SEK
Jan 1, 2021
-403.10 SEK
The Biosergen Net Margin history
YEARNet MarginYoY
-403.10 %+147.38%
-162.95 %-60.49%
-412.48 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biosergen Stock analysis

What does Biosergen do? Biosergen AB is a biopharmaceutical company headquartered in Solna, Sweden. The company went public on June 24, 2021, with its ticker symbol BIOSGN.ST and ISIN SE0026821852. Biosergen AB conducts biopharmaceutical research and development through its subsidiary Biosergen AS, utilizing laboratory facilities in Trondheim, Norway, and other global locations. The company is focused on developing BSG005, an antifungal drug that has shown safety and potency benefits compared to existing treatments. BSG005 is designed to address invasive fungal infections affecting immune-compromised patients, including those with AIDS, cancer, or who have undergone transplants. At equivalent doses, BSG005 has demonstrated a three- to fourfold higher potency against targeted fungal strains than current standard treatments, while avoiding the kidney toxicity associated with other drugs in its class. Biosergen AB operates within the Health Care sector, specifically in the Biotechnology industry. The company's website is biosergen.net, providing further information about its research and development activities. The firm's primary focus remains on advancing BSG005 through clinical development, targeting a significant unmet medical need in the treatment of fungal infections among vulnerable patient populations. Biosergen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biosergen stock

Net Profit Margin of Biosergen is -403.10 % in 2021.

Net Profit Margin of Biosergen changed from -162.95 % to -403.10 %, representing a 147.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Biosergen since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Biosergen with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Biosergen

All Key Metrics — Biosergen